This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Vigil Neuroscience Stock (NASDAQ:VIGL) Get Vigil Neuroscience alerts:Sign Up Key Stats Today's Range$8.05▼$8.0550-Day Range$7.95▼$8.0852-Week Range$1.75▼$8.10VolumeN/AAverage Volume1.47 million shsMarket Capitalization$383.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vigil Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel therapies to address neuroinflammation in debilitating neurodegenerative diseases. The company’s research centers on the TAM family of receptor tyrosine kinases, which regulate microglial activation and clearance processes in the central nervous system. By modulating these pathways, Vigil aims to slow or halt the progression of conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Leveraging a proprietary discovery platform, Vigil identifies and optimizes small-molecule modulators with high specificity for TAM receptors and favorable brain penetration. Its lead candidates have demonstrated neuroprotective and anti-inflammatory effects in preclinical models and have progressed into early clinical development. Vigil plans to broaden its pipeline to additional indications where chronic neuroinflammation plays a key role. Founded in 2019 and headquartered in New York City, Vigil Neuroscience is led by a team of seasoned professionals in neuroscience, drug discovery and clinical development. The company collaborates with academic institutions and industry partners and is supported by venture investors with deep expertise in life sciences, all with the shared goal of delivering transformative therapies for patients living with neurodegenerative disorders.AI Generated. May Contain Errors. Read More Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIGL Stock News HeadlinesVigil Neuroscience Inc Merger and Leadership ChangesAugust 13, 2025 | theglobeandmail.comVIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGLJuly 14, 2025 | businesswire.comYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answer to a multi-variable problem. Withdrawal sequencing, sequence-of-returns risk, Roth conversion timing, and legacy goals can all shift your real number significantly. Research from Vanguard suggests advisor best practices - covering allocation, rebalancing, tax management, and behavioral coaching - may add roughly 3% in net annual return potential. Morningstar's 2025 data shows the average investor return gap is 1.2% per year due to mistimed buying and selling. Get matched with a fiduciary advisor in your area at no cost and with no obligation to hire.August 2 at 1:00 AM | SmartAsset (Ad)Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comWall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - NasdaqJune 27, 2025 | nasdaq.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comVigil Neuroscience halts Phase 2 trial for ALSP treatmentJune 5, 2025 | investing.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...June 5, 2025 | morningstar.comMSee More Headlines VIGL Stock Analysis - Frequently Asked Questions How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) released its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an IPO on Thursday, January 6th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of Vigil Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), ExxonMobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD). Company Calendar Last Earnings5/07/2025Today8/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 VIGL's financial health is in the Green zone, according to TradeSmith. VIGL has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VIGL CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees40Year Founded2020Profitability EPS (Trailing Twelve Months)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-111.70% Return on Assets-74.67% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book4.60Miscellaneous Outstanding Shares47,690,000Free Float39,099,000Market Cap$383.90 million OptionableNot Optionable Beta3.33 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:VIGL) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredApple just sent a powerful signal to investorsApple just crossed a $5 trillion market value as shares climbed 25% this year, fueled by new product launches ...Mode Mobile | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredA 50-year dollar arrangement just ended - what it means for youIn 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...Golden Portfolio | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
